Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

focafoca99 May. 12 at 9:50 PM

$ABBV elected its Class II directors and ratified EY as auditor at its 2026 annual meeting. https://www.rapidticker.com/news/abbv-sec-filing-8-k-5cb052

0 · Reply

55X_ROI_Q1_2026 May. 12 at 9:02 PM

$SLS $ABBV Sub $10 is C.A.P. PSA: for anyone who doesn't know. Azacitidine + Venetoclax, the BAT- Best Available Treatment for Control Arm Patients - Recently FAILED 3 Large Phase 3 AML Trials conducted by ABBV. VIALE-M - AML First Remission (CR1) Maintenance Trial - FAILED VIALE-T - AML Post Transplant Maintenance Trial - Failed ABBV Knows its Gps / Doing what its done in all Previous Trials, Prevent Relapse and Extend Survival - including in 2 Previous Phase 2 AML Remission Maintenance Trials. Gps Immunotherapy is worth $40B to Big Pharma. - I've been here a while and done much dd if anyone wants to get up to speed, scroll my posts.

0 · Reply

55X_ROI_Q1_2026 May. 12 at 8:51 PM

$SLS @onthebalance How many repositioners just Got Left Off the Boat?? LOL GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.

0 · Reply

TrendSpider May. 12 at 8:05 PM

Vitals improving 🩺 $ABBV

0 · Reply

TalkMarkets May. 12 at 6:13 PM

10 Low Risk #Dividend Growth Stocks $CWT $ADP $ABBV $TGT $BKH https://talkmarkets.com/article/10-low-risk-dividend-growth-stocks-1778609266

0 · Reply

Gramma May. 12 at 5:08 PM

$ABBV nice move and always a great dividend,owned for 10 yrs

0 · Reply

Garibs May. 12 at 4:57 PM

$ABBV there is 210+

0 · Reply

Donib11 May. 12 at 4:56 PM

$ABBV dare I say 215 today? 😳

0 · Reply

FemaleGermanInvestor May. 12 at 4:45 PM

$ABBV holding so strong in a weak market!

0 · Reply

Garibs May. 12 at 3:29 PM

$ABBV great stock. Calls printed!

0 · Reply

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 6 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

2026-05-05T12:32:52.000Z - 7 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

May 5, 2026, 8:05 AM EDT - 7 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

2026-05-04T12:13:35.000Z - 8 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

May 1, 2026, 3:05 PM EDT - 11 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 11 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 12 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

2026-04-30T18:00:46.000Z - 12 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T13:31:03.000Z - 12 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Apr 30, 2026, 9:00 AM EDT - 12 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

2026-04-30T10:15:57.000Z - 12 days ago

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:14:18.000Z - 12 days ago

AbbVie upgraded to Buy from Neutral at BofA

2026-04-29T16:41:09.000Z - 13 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:39:58.000Z - 13 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:07.000Z - 13 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-04-29T13:25:07.000Z - 13 days ago

AbbVie says ‘especially pleased’ with immunology and neuroscience results

Apr 29, 2026, 9:00 AM EDT - 13 days ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 13 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

2026-04-29T12:15:43.000Z - 13 days ago

AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67

2026-04-29T12:13:45.000Z - 13 days ago

AbbVie raises FY26 adjusted EPS view to $14.08-$14.28 from $13.96-$14.16

Apr 29, 2026, 7:50 AM EDT - 13 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 13 days ago

AbbVie Reports First-Quarter 2026 Financial Results

2026-04-29T11:05:22.000Z - 13 days ago

Options Volatility and Implied Earnings Moves Today, April 29, 2026

AMZN F GOOG GOOGL META MSFT QCOM

Apr 28, 2026, 8:00 AM EDT - 14 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 14 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 15 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 19 days ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 19 days ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 20 days ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 20 days ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 22 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 4 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 4 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 4 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 8, 2026, 1:38 PM EDT - 4 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 8:00 AM EDT - 4 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 7, 2026, 9:53 AM EDT - 5 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 5 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 3, 2026, 11:08 AM EDT - 5 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 5 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 5 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 5 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 5 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 6 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 27, 2026, 10:00 AM EDT - 6 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 20, 2026, 12:11 PM EDT - 7 weeks ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 7 weeks ago

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 3:00 AM EDT - 7 weeks ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 18, 2026, 2:23 PM EDT - 7 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Feb 24, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 12:03 PM EST - 2 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 11:00 AM EST - 2 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 20, 2026, 2:00 AM EST - 2 months ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 19, 2026, 9:37 AM EST - 2 months ago

AbbVie Declares Quarterly Dividend

Feb 13, 2026, 10:00 AM EST - 3 months ago

AbbVie Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 11, 2026, 6:49 PM EST - 3 months ago

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 5:13 PM EST - 3 months ago

Abbvie sues US health agency over Botox

Feb 4, 2026, 9:00 AM EST - 3 months ago

AbbVie Earnings Call Transcript: Q4 2025

Feb 4, 2026, 8:34 AM EST - 3 months ago

AbbVie Revenue Rises on Immunology Growth

focafoca99 May. 12 at 9:50 PM

$ABBV elected its Class II directors and ratified EY as auditor at its 2026 annual meeting. https://www.rapidticker.com/news/abbv-sec-filing-8-k-5cb052

0 · Reply

55X_ROI_Q1_2026 May. 12 at 9:02 PM

0 · Reply

55X_ROI_Q1_2026 May. 12 at 8:51 PM

0 · Reply

TrendSpider May. 12 at 8:05 PM

Vitals improving 🩺 $ABBV

0 · Reply

TalkMarkets May. 12 at 6:13 PM

10 Low Risk #Dividend Growth Stocks $CWT $ADP $ABBV $TGT $BKH https://talkmarkets.com/article/10-low-risk-dividend-growth-stocks-1778609266

0 · Reply

Gramma May. 12 at 5:08 PM

$ABBV nice move and always a great dividend,owned for 10 yrs

0 · Reply

Garibs May. 12 at 4:57 PM

$ABBV there is 210+

0 · Reply

Donib11 May. 12 at 4:56 PM

$ABBV dare I say 215 today? 😳

0 · Reply

FemaleGermanInvestor May. 12 at 4:45 PM

$ABBV holding so strong in a weak market!

0 · Reply

Garibs May. 12 at 3:29 PM

$ABBV great stock. Calls printed!

0 · Reply

Garibs May. 12 at 2:24 PM

$ABBV let's see 215

0 · Reply

Knot2 May. 12 at 1:56 AM

$ABBV looks higher

0 · Reply

Garibs May. 11 at 7:25 PM

$ABBV looked promising at 205.. let's see what the week brings. Fair market value is 400 btw

0 · Reply

Oldpuck May. 11 at 6:40 PM

$ABBV Probably end red the way this has been going

0 · Reply

Hedgieguy75 May. 11 at 5:35 PM

$SKIN think this actually has a shot to clear $1 by end of week.. This is just getting started .. Incoming gapper.... but you do you $ABBV ..

0 · Reply

dewmoore May. 11 at 2:35 PM

$SLS GPS: We are now 42 months since the 72nd event, and still no 80th event in sight. Simply amazing for a Phase 3 study now in its 56th month! But the KICKER is this hidden gem: SLS009 (tambiciclib). In a disease where patients are typically given 2.5 months to live, they are still alive many months later. The "Uncalculable" Success is the real story here. The CEO highlighted that in the most critical group—patients with only one prior line of therapy—the survival rate is so strong they literally cannot calculate a median overall survival (mOS) yet. Think about that: out of the 12 patients in that group, not even 7 have died since it started over a year ago. To go from a 2.5-month life expectancy to a survival trend so high it breaks the math is a MIRACLE. The nuance of this survival data in AML is the ultimate game-changer!!! LFG SLS not selling until $100 and even then won't be selling all because of the LOOMING buyout war between these 4: $LLY $PFE $MRK $ABBV

2 · Reply

mr_Apex May. 11 at 2:01 PM

$ABBV 15 MAY 26 | 217.5 CALL Entry: $0.24

0 · Reply

Th3M4skedSt0nker May. 11 at 1:59 PM

$KYTX 5. Partnership or strategic interest hints This is where the speculative fireworks will happen. Big Pharma is aggressively moving into autoimmune and cell therapy: • $RHHBY • $BMY • $ABBV • Novartis • $GILD The entire sector is watching autoimmune CAR-T closely. Kyverna recently strengthened commercial leadership hiring ahead of launch preparation. A bullish earnings call could hint at: • strategic partnership discussions • manufacturing collaborations • commercialization support • regional licensing • or even inbound acquisition interest Even subtle language will ignite biotech momentum. 💲🔥💲🔥💲

0 · Reply

Garibs May. 11 at 12:51 AM

$ABBV what are the odds we see 210+ in the next week or two?

0 · Reply

perchedcats May. 10 at 2:47 AM

$VKTX no partnership or BO please - going alone is best way to extract value here. ph3 results about 1 year away - other catalysts along the way: maintenance study, amylin… maybe they could also announce european partner / licensing or for japan and keep US market. these are better options. unless they partnered with $ABBV 50/50- that‘s cleaner than with $LLY or $NVO given their existing / dominating drugs (TZP in SQ / WEGOVY in Oral)

1 · Reply

MarketBeat May. 9 at 2:08 PM

https://marketbeat.com/a/8644330/ $ABBV AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

0 · Reply

UsingAGodAlgorithm May. 8 at 9:56 PM

$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $ABBV $PLTR $MU $MA

0 · Reply

Market Cap	356.37B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	19.89
Forward PE	14.17
Profit Margin	6.91%
Debt to Equity Ratio	-20.91

Volume	7,044,062
Avg Vol	6,985,884
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	50%
Beta	0.32
Analysts	Strong Sell
Price Target	$251.03